Sol-Gel Technologies (SLGL) has released an update.
Sol-Gel Technologies reports progress in their dermatology-focused pipeline, including a Phase 3 trial for Gorlin Syndrome treatment, a proof-of-concept study for Darier disease, and a compassionate use case showing promising results. Additionally, they’ve inked a deal with Beimei Pharma to commercialize TWYNEO in various Asian markets, with potential earnings of up to $15 million. The company also maintains a healthy financial runway into the second half of 2025.
For further insights into SLGL stock, check out TipRanks’ Stock Analysis page.
